Combination treatment for FGFR2-positive bile duct cancer
Part of Cancer clinical trials.
This study tests a combination of two medications—pemigatinib and durvalumab—for people with advanced bile duct or gallbladder cancer that has stopped responding to prior treatment and has a specific genetic change (FGFR2 fusion). The goal is to see if this combination can shrink or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or spreading gallbladder or bile duct cancer that has not responded to one prior treatment.
- Your tumor must have a specific genetic marker called FGFR2 fusion or rearrangement.
- You are in generally good health (able to do daily activities, with a life expectancy of at least 3 months).
- You can provide a tumor tissue sample for testing and have measurable disease on scans.
- You are willing to use contraception if applicable and follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.